Oxford PharmaGenesis demonstrates verifiable medical AI
Dr. Kim Wager showcased how agentic medical AI can maintain data provenance using OriginTrail's Decentralized Knowledge Graph.
The provenance problem:
- Pharmaceutical research has clear traceability: trial β publication β review β guideline
- This chain breaks when knowledge enters AI models
- Clinical decisions lose their verifiable source
The solution: Oxford PharmaGenesis, trusted by 8 of the world's top 10 pharma companies, is building on the Decentralized Knowledge Graph to preserve provenance throughout the AI reasoning process.
This approach ensures agentic science maintains scientific standards and verifiable sources.
π Pharma already solved provenance. Every claim traces back: trial β publication β review β guideline. Then knowledge reaches an AI model, and the chain breaks. Trusted by 8 of the world's top 10 pharma companies, Oxford PharmaGenesis is building on Decentralized
How do we make medical AI trustworthy? Dr. Kim Wager of Oxford PharmaGenesis showcased a live demo of agentic medical AI grounded in verifiable data provenance, powered by the @origin_trail Decentralized Knowledge Graph.
AidTrust Uses Digital Product Passports to Track Donated Medicine Distribution
**AidTrust**, developed with BSI and powered by OriginTrail, brings transparency to medical supply distribution for donated medicines. The system uses **Digital Product Passports (DPPs)** - machine-readable data attached to products that AI systems can verify and act upon. This ensures donated medicines reach intended patients rather than being diverted or lost in supply chains. The approach demonstrates practical applications of verifiable data in healthcare logistics, where tracking and authenticity matter for patient safety.
Umanitek Guardian Uses Origin Trail DKG for Real-Time Threat Analysis
**Umanitek Guardian** is leveraging **Origin Trail's Decentralized Knowledge Graph (DKG)** to address critical challenges in threat analysis. **The Problem:** - Scattered signals across platforms - Missing context - Unverifiable sources **The Solution:** DKG provides agents with shared, verifiable memory that enables: - **Source tracing**: Every signal can be traced back to its origin - **Persistent context**: Information stays attached across networks - **Connected analysis**: Threats assessed with full context This infrastructure allows Umanitek Guardian to analyze and trace threats in real time with verifiable data provenance.
DKG v10 Enables AI Agents to Share Verifiable Knowledge and Reach Consensus
**DKG v10 introduces a new architecture for AI systems** built on reliable memory, shared context, and verifiable knowledge. **How it works:** - AI agents process information privately - Results are compared within a shared knowledge graph - Conclusions surface on-chain only when consensus is reached **Real-world validation:** Five independent AI agents analyzing medical data from PubMed, ClinicalTrials.gov, and safety databases converged on identical findings without coordination. Each conclusion includes verifiable provenance stamps. **The shift:** Instead of isolated AI systems that rediscover the same information, DKG v10 creates cumulative knowledge where each agent builds on previous work. The Decentralized Knowledge Graph is now live as open-source infrastructure, designed as shared memory accessible to both humans and AI agents.
Porsche Family Office Partner Highlights OriginTrail's AI Infrastructure Role

**Chris Rynning**, Chairman of Umanitek and Managing Partner at AMYP Ventures AGβpart of the Pich-Porsche family officeβdiscussed OriginTrail's critical role in providing infrastructure for the AI era. **Key Points:** - AMYP Ventures AG is connected to the prominent Pich-Porsche family office - OriginTrail is positioned as essential infrastructure for AI development - The endorsement comes from a major institutional investor with ties to the automotive industry The statement underscores growing institutional interest in decentralized infrastructure solutions that support AI applications, particularly from established European investment entities.